A b s t r a c t -When clinicians test a new treatment PTOcedure, they 
Introduction
When clinicians conduct treatment experiments, called clinical trials, they have to recruit participants from current patients. To select prospective participants, clinicians analyze the data of available patients and identify patients with appropriate medical conditions. This analysis has traditionally been a manual process, and studies have shown that clinicians miss up to 60% of the matching patients, which delays the completion of clinical trials [7, 171. To address this problem, several researchers built expert systems to help clinicians select trial participants. crease the number of selected patients by a factor of three [13, 14, 151.
The National Cancer Institute created a search engine for selecting clinical trials, available through the Internet at www.cancer.gov/search/clinical.trials.
It
prompts a user to answer several questions about a patient, and gives a list of potentially matching trials; h o w ever, it does not determine whether the patient satisfies all of the requirements of these trials. rule-based system for the same task [l] . We have continued their work, built a new version of the rulebased system [6, 9, 101 , and applied it to selecting patients for breast-cancer trials at the Moffitt Cancer Center, located on campus of the University of South Florida. We outline the design of this system and present an empirical evaluation of its effectiveness. The system collects data until it can determine whether the eligibility expression is TRUE or FALSE. For example, if a clinician uses the system to determine a patient's eligibility for the trial in Figure l(b) , it first asks about the patient's sex and age. If the patient satisfies the corresponding conditions, it asks for the mammogram results, and then requests the biopsy and electre cardiogram data. The ordering of tests depends on their costs and on the amount of information provided by test results. The system begins with the mammogram because it is cheaper than the other tests and provides data for two clauses of the eligibility expression.
Knowledge base

Selection of participants
We have built a knowledge base for the breast-cancer trials at the Moffitt Cancer Center, including five completed trials and ten current trials, and applied the system to retrospective data from the Moffitt patients who have had a breast-cancer surgery in the last three years. We have discarded the patients whose available records are incomplete, and used all remaining patients, which include 187 past patients and 169 current patients.
We have compared the results of automated trial selection for these patients with the manual selection by hloffitt clinicians. The system has identified all eligible patients for each trial, whereas the clinicians have selected about one-third of the eligible patients. We summarize the results for the past patients in Table l(a) , and the results for the current patients in Table l(b).
The "participants" column shows the number of actual participants of each trial; the "other eligible" column gives the number of the other eligible patients identified by the system.
For every current patient who did not participate in a matching trial, we have checked whether she participated in any other trial, and we show the results in Table 2 . We have not done a similar analysis for the past patients due to insufficient data. The "incompatible" column in Table 2 includes the number of eligible patients who did not participate in a specified trial because of participation in another incompatible trial. The "compatible" column shows the number of patients who participated in another compatible trial, and could also have participated in the specified trial. Finally, the "no other trial?' column gives the number of eligible patients who have not participated in any trial.
The results show that the system can identify eligible patients who have not been selected by clinicians; thus, it can increase the number of trial participants.
For the patients in the reported experiments, it could increase the overall number of participants by a factor of three. In particular, it has found prospective participants for some trials with a very small number of manually selected patients. For example, it has found nineteen matching patients for trial 12385, which currently has no participants, and twenty-six patients for trial 11931, which has only two participants.
Cost reduction
If the available patient records do not provide enough data for trial selection, clinicians perform medical tests as part of the selection process. They can reduce the overall test cost by first ordering inexpensive tests, and then using their results to avoid some expensive tests.
The system suggests the ordering of tests that reduces their expected cost. After getting the results of the first test, it re-evaluates the need for the other tests and revises their ordering. The choice of the first test is based on three criteria. The system scores all required tests according to these criteria, computes a linear combination of the three scores for every test, and chooses the test with the highest score. 
3.
Number of related clauses. The system prefers the tests that provide data for large number of clauses in the eligibility expression. The system disregards the costs of tests performed in the normal course of treatment, and accounts only for the costs related to the trial selection. For example, if a patient needs a mammogram regardless of trial participation. the system views it as a zero-cost test. On the other hand, if the only purpose of the biopsy and electrocardiogram is to select trials, the system uses the heuristics to order these tests.
We show the mean test costs with and without the ordering heuristics in Table 3 , and give a graphical view of the cost savings in Figure 2 . The results confirm that the heuristics reduce the cost of the selection p r e cess. Six clinical trials have incurred selection costs; the heuristics have reduced the costs for four of these trials, and have not affected the costs for the other two trials.
The results in Table 3 (a) differ from similar experiments with an earlier version of the system [GI, because of two changes to the system. First, the current version disregards the costs of the tests required for the regular treatment, which do not affect the trial-selection expenses, whereas the earlier version counted all costs. Second, some costs in the old system were out-of-date, and we have corrected them based on the data from the Moffitt accounting department.
Reduction of data entry
The system tries to minimize not only the overall cost of medical tests, hut also the amount of data entry, that is, the number of questions asked about a patient. For each question, it estimates the probability that the answer will lead to an immediate acceptance or rejection of the trial, and it gives preference to the questions with the highest probability of an immediate decision. Thus, when a clinician enters the available data, the system asks the related questions in the decreasing order of the immediate-decision probabilities. It estimates these probabilities from past experience with other patients. For each question, it determines the percentage of past answers that have led to immediate decisions, and uses this percentage as the probability estimate.
We have evaluated the effectiveness of this ordering heuristic for six clinical trials, using the data from the 169 current patients. We have performed ten-fold crossvalidation; that is, we have used 90% of the patients to compute the related probabilities, and then measured the mean number of questions for the other 10%.
We show the results with and without the ordering heuristic in Table 4 , and give a graphical view of the Clinical Figure 3: Number of questions with and without the reordering heuristic, for the 169 current patients.
same results in Figure 3 . The heuristic has reduced the number of questions for all six trials; the reduction ranges from 1% to 29%, and its mean is 15%. The results confirm that the accumulated statistical data help reduce the number of questions.
Concluding remarks
We have developed an expert system that selects clinical trials for eligible patients. Experiments have confirmed that the system can increase the number of clinical-trial participants. They have also shown that the ordering of related medical tests affects the overall test cost, and the implemented heuristics can reduce this cost.
